Pfizer and Cellectis enter into global strategic cancer immunotherapy collaboration
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) and Cellectis (Paris:ALCLS) have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets.
Pfizer opens new state-of-the-Art research and development site in Cambridge, Massachusetts
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has announced the opening of a new 280,000 square-foot Research and Development (R&D) hub in Cambridge, Mass. The new Pfizer facilities in Kendall Square bring together 1,000 colleagues from three area locations and position Pfizer in closer proximity to leading academic institutions, hospitals and patient organizations.
Mindprint implements market-leading automation solution for Ockham Oncology
- Details
- Category: Business
Mindprint Inc. and Ockham Development, Inc. have implemented an innovative automation software system to help the global CRO manage trials efficiently to ensure a more focused approach to its core oncology mission.
Sanofi and Lilly announce licensing agreement for Cialis® (tadalafil) OTC
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and Eli Lilly and Company (NYSE: LLY) have announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED).
Bristol-Myers Squibb and Syngene International extend research collaboration
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb (NYSE:BMY) and Syngene International, India's largest contract research organization, have announced a five-year extension of their drug discovery and development collaboration in India. Financial terms were not disclosed.
AstraZeneca updates on the rapid progress of its oncology pipeline at ASCO 2014
- Details
- Category: AstraZeneca
AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for analysts and investors on 2 June 2014, as compelling data from over 40 scientific abstracts related to AstraZeneca and MedImmune investigational medicines were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
Bayer and Orion Corporation to develop and commercialize novel prostate cancer treatment
- Details
- Category: Bayer
Bayer has entered into a global agreement with Orion Corporation, a pharmaceutical company based in Espoo, Finland, (Nasdaq OMX Helsinki: ORNAV and ORNBV) for the development and commercialization of the compound ODM-201, an investigational novel oral androgen receptor inhibitor. ODM-201 is in clinical development for the treatment of patients with prostate cancer.
More Pharma News ...
- Pfizer and the Avon Foundation for Women announce $1 million grants program
- Novartis launches 7-Day Challenge to 'Live Like You' enabling people with MS to better understand their lives with MS
- Pfizer brings frequent heartburn relief OTC with new Nexium® 24HR
- Clarification regarding Pfizer statement
- AstraZeneca rejects final proposal from Pfizer
- Abbott enhances its position in fast-growing Latin American market
- MedImmune and Incyte announce collaboration on immuno-oncology combination clinical trial